Substituted bicyclic compounds as bromodomain inhibitors

A compound of Formula I:

• or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof,
• wherein:
• W1 is selected from N and NH;
• W2, and W3 are selected from C and N;
• Z1 and Z2 are selected from a single bond and a double bond;
• R1 is selected from carbocycle (C5-C10) and heterocycle (C2-C10) optionally substituted with 1 to 5 groups independently selected from R5;
• R2 is selected from hydrogen and alkyl (C1-C6) optionally substituted with halogen and/or hydroxyl;
• R3 is selected from alkyl (C1-C6) optionally substituted with halogen and/or hydroxyl, with the proviso that if R2 and R3 are methyls, then R1 is different from:
• wherein A is selected from hydrogen, halogen, methoxy, —CN, —NO2, —COOMe, and —CONMe2;
• R4 if present, is selected from hydrogen, alkyl (C1-C10), carbocycle (C3-C10), and heterocycle (C2-C10) optionally substituted with 1 to 5 groups independently selected from R5;
• each R5 is independently selected from deuterium, alkyl(C1-C6), alkoxy(C1-C6), amino, —NHC(O)NH-alkyl(C1-C6), halogen, amide, —CF3, —CN, —N3, ketone (C1-C6), —S(O)-alkyl(C1-C4), —SO2-alkyl(C1-C6), thioalkyl(C1-C6), —COOH, and ester, each of which may be optionally substituted with hydrogen, F, Cl, Br, —OH, —NH2, —NHMe, —OMe, —SMe, oxo, and/or thio-oxo;
• X is selected from —CH2— optionally substituted with 1 to 2 groups independently selected from R5;
• Y is selected from N and CH;
• wherein if W3 is C, then W2 is N, W1 is NH, Z1 is a double bond, Z2 is a single bond, and R4 is absent;
• and
• wherein if W3 is N, then W2 is C, W1 is N, Z1 is a single bond and Z2 is a double bond.